米索前列醇预防剖宫产产后出血的临床分析

目的探讨米索前列醇预防剖宫产产后出血临床效果。方法选择我院2011年5月至2012年5月剖宫产分娩产妇共80例,所选患者随机分为观察组和对照组。所选两组患者均实时腰硬联合麻醉下剖宫产,对照组产妇在胎儿娩出后注射缩宫素20IU,观察组在胎儿娩出后给予米索前列醇,直肠置入给药,剂量为400μg。记录两组产妇产后2h、产后24h内的出血量,并观察用药后不良反应发生情况。结果观察组产后2h出血量低于对照组,差异有统计学意义(P<0.05);观察组产后24h出血量低于对照组,差异有统计学意义(P<0.05);观察组产后出血发生率低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论直肠置入米索前列醇预防剖宫产产后出血效果显著,值得借鉴。     

米索前列醇直肠给药联合缩宫素预防产后出血临床观察

目的观察米索前列醇直肠给药联合缩宫素预防产后出血的效果。方法选择我院2007年1月-2009年1月住院分娩,有产后出血高危因素的阴道分娩产妇120例,随机抽取60例米索前列醇直肠给药联合缩宫素预防产后出血为观察组。另60例产妇单用缩宫素预防产后出血为对照组,观察两组产妇第三产程时间,产后2h的出血量,产后出血的发生率及药物不良反应。结果比较第三产程时间,观察组较对照组短,差异有统计学意义（P〈0.05）;产后出血量及产后出血发生率相比,观察组均较对照组低,差异有统计学意义（P〈0.05）。结论米索前列醇直肠给药联合缩宫素缩短第三产程的时间,减少产后出血量,是一种安全、简单、高效的预防产后出血的方法,值得临床推广应用。     

米索前列醇与卡前列素氨丁三醇治疗剖宫产产后出血临床对比观察

目的:比较米索前列醇与卡前列素氨丁三醇治疗剖宫产产后出血的临床疗效.方法:选取2014年11月～2016年11月我院收治的60例剖宫产产后出血产妇,随机分为两组,每组30例.对照组服用米索前列醇治疗,观察组肌肉注射卡前列素氨丁三醇治疗.比较两组产妇产后出血量和不良反应发生情况.结果:对照组产妇产后2h及产后1d出血量明显高于观察组,差异有统计学意义(P<0.05);对照组不良反应发生率(26.67％)明显低于观察组(6.67％),差异有统计学意义(P<0.05).结论:与米索前列醇相比,卡前列素氨丁三醇治疗剖宫产产后出血疗效确切,能显著减少产后出血量,降低不良反应发生率,安全性较高,利于产妇产后恢复,值得临床推广.     

不同给药方法下米索前列醇在产后出血预防中的临床效果及安全性分析

目的探讨不同给药方法下米索前列醇在产后出血预防中的临床效果及安全性分析。方法收集我院2012年4月至2014年2月收治的住院分娩的产妇93例,随机分为宫内给药组、直肠给药组、口服组,各31例。3组产妇均在胎儿完全娩出后注射催产素20μg,同时采用三种不同的给药方法给予米索前列醇。宫内给药组:胎盘完全娩出后,干纱布擦净子宫腔,将米索前列醇400μg放入宫腔内;直肠给药组:将米索前列醇400μg放置产妇直肠内;口服给药组:舌下含服米索前列醇400μg。记录产妇第三产程时间、2 h出血量、24 h出血量及不良反应情况。结果三组产后出血发生率对比,无显著性差异(P>0.05);三组第三产程时间对比,无显著性差异(P>0.05);2 h出血量和24 h出血量对比,宫内给药组和口服给药组明显优于直肠给药组(P<0.05);三组产妇不良反应发生率为:宫内给药组12.9%,直肠给药组19.4%,口服给药组9.7%。结论米索前列醇宫内给药能有效预防产妇产后出血,安全有效,是临床上预防产后出血的最佳途径。     

缩宫素联合米索前列醇治疗产后出血疗效分析

目的观察缩宫素膜合米索前列醇对产后出血的治疗效果。方法将从2011年2月～2011年12月期间到本院分娩的82例产妇随机均分为对照组及观察组,产后给予对照组缩宫素肌肉注射预防产后出血,给予观察组缩宫素静脉滴注及米索前列醇直肠置入,记录两组产妇第三产程时间,观察两组产妇产后出血情况及不良反应发生情况。结果观察组第三产程时间明显短于对照组,产后2h、24h出血量少于对照组,两组比较差异均具有统计学意义(P<0.05);不良反应发生率两组比较差异无统计学意义(P>0.05)。结论缩宫素联合米索前列醇治疗产后出血,产妇的子宫收缩能力增强,出血量明显减少,值得临床广泛推广。     

米索前列醇两种给药途径预防产后出血的疗效比较

目的 探讨米索前列醇两种给药途径预防产后出血的疗效比较.方法 将2015年12月~2016年12月在我院妇科治疗的110例自然分娩产妇随机分为两组,为预防产后出血均服用米索前列醇,对照组采用直肠给药,观察组采用舌下含服,比较两组产妇产后出血率、2h及24h出血量、第3产程时间、红细胞压积、血色素及分娩前后血压.结果 观察组产后出血率、2h及24h出血量、第3产程时间均明显少于对照组,差异有统计学意义(P<0.05);观察组红细胞压积下降≥10%率、血色素下降≥30g·L-1率与对照组相比,差异有统计学意义(P<0.05);观察组分娩前血压、分娩后血压与对照组相比,无明显差异(P>0.05).结论 舌下含服米索前列醇预防产后出血效果显著,有利于缩短产程,减少产后出血量,降低产后出血率,具有积极的临床意义.     

不同用药途径对米索前列醇预防产后出血效果的影响比较

目的:探讨不同用药途径对米索前列醇预防产后出血效果的影响.方法:选取2016年5月～2017年5月在我院进行顺产的孕妇400例,按整群抽样分层法分为观察组(n=200)和对照组(n=200),对照组产妇在儿前肩娩出后,给予缩宫素+米索前列醇直肠给药途径预防,观察组给药时间同对照组,给予缩宫素+米索前列醇舌下含服途径预防,观察两组疗效.结果:观察组第三产程时间显著短于对照组(P<0.05),产后2h出血量和产后24h出血量低于对照组(P<0.05);观察组红细胞压积下降≥10％及血色素下降≥30g/L比例均显著低于对照组(P<0.05);两组不良反应发生率差异不显著(P>0.05).结论:米索前列醇舌下含服途径预防产后出血效果显著优于直肠给药途径,临床应用安全、有效.     

预防产后出血应用米索前列醇不同给药方式联合缩宫素的临床价值研究

目的探讨产后出血预防中米索前列醇不同给药方式联合缩宫素的临床应用价值。方法筛选2018年1月至2019年1月期间在我院分娩的170例产妇为实验对象,使用入院单双号日期均分为两组,各85例,在产后出血预防中都使用宫缩素,同时使用米索前列醇,在给药方式上对照组直肠给药、实验组舌下含服,对比两组应用效果。结果产后出血发生率方面实验组为4.71%、对照组为5.88%,组间差异无统计学意义(P>0.05);实验组与对照组产后2 h、24 h出血量差异无统计学意义(P>0.05);用药不良反应方面实验组为2.35%、对照组为3.53%,差异无统计学意义(P>0.05)。结论米索前列醇不同给药方式联合缩宫素在预防产后出血上均有着较高的应用价值,无论是直肠给药还是舌下含服都能很好的控制出血量,且用药安全性高,临床中值得推广应用。     

米索前列醇联合缩宫素预防产后出血130例临床观察

目的观察米索前列醇联合缩宫素预防产后出血的疗效。方法选择足月妊娠产妇260例,随机分为对照组和观察组各130例,两组产妇均于胎儿娩出后立即给药,对照组给予缩宫素治疗,观察组在对照组基础上加用米索前列醇200μg舌下含服,比较两组临床疗效。结果观察组第三产程时间短于对照组,产后2h及24h出血量少于对照组,两组比较差异均有统计学意义(P<0.05);药物不良反应及新生儿阿氏评分两组间差异无统计学意义(P>0.05)。结论米索前列醇联合缩宫素可有效减少产后出血量,优于单用缩宫素组,值得临床推广应用。     

米索前列醇预防剖宫产产后出血的临床疗效观察

目的:探讨米索前列醇预防剖宫产产后出血的临床效果。方法:以我院117例剖宫产者为研究对象,分组通过不同给药途径给予米索前列醇和宫缩素,观察产后出血量及不良反应情况。结果:口服或直肠置入米索前列醇产妇产后平均出血量均明显少于使用缩宫素者;而直肠置入效果明显优于口服而不良反应少,比较差异均有统计学意义(P<0.05)。结论:剖宫产术中使用米索前列醇直肠给药,预防产后出血效果好,不良反应小,对减少产后出血量,降低产妇的病死率有重要意义,值得临床进一步研究推广。     

Analgesia induced by brief footshock is inhibited by 5-hydroxytryptamine but unaffected by antagonists of 5-hydroxytryptamine or by naloxone

Exposure to footshock (1 mA) for 30 sec induced a marked analgesia that was enhanced by pretreatment with the 5HT synthesis inhibitor, p-chlorophenylalanine, and attenuated by the 5HT releasing drugs p-chloroamphetamine and fenfluramine, by the 5HT re-uptake inhibitor, fluoxetine and by the 5HT agonists, 5-methoxy-N,N-dimethyltryptamine and MK212. However, agonists, quipazine and trifluoromethylphenylpiperazine, with greated reported affinities for 5HT binding sites on rat brain membranes than MK212 were without effect as were the antagonists metergoline, methysergide, cyproheptadine, mianserine and methiothepin. The specific opioid antagonist naloxone was also without effect. The results in general indicate that analgesia induced by brief footshock (1 mA, 30 sec) is inversely related to 5HT availability but thereis little evidence of involvement of known 5HT receptors.     

Synergism by caffeine and by cocaine of the motor control deficit produced by midazolam

To evaluate the effects of caffeine and cocaine on the impairment of discriminative motor control produced by midazolam, rats were trained to hold a force transducer operated with a paw so that it remained between upper and lower limits of a force band for a continuous 1.5-s period to deliver each food pellet. Acute doses of 3 mg/kg midazolam SC impaired motor performance. Except for one animal, caffeine (10-40 mg/kg IP) had little or no effect on performance, while cocaine (3.75-22.5 mg/kg IP) produced dose-related impairment. When each dose of caffeine was combined with 3 mg/kg midazolam, a marked synergism in motor performance impairment occurred. Cocaine plus midazolam produced mainly an additive synergism. The conspicuous synergistic action of caffeine on the motor control deficit produced by midazolam contrasts with the typical antagonism found between the benzodiazepines and methylxanthines when performance is evaluated by psychomotor tests not requiring fine motor control.     

Deamination of beta-phenylethylamine by monoamine oxidase--inhibition by imipramine

The oxidative deamination of tyramine (Tyr), 5-hydroxytryptamine (5-HT), and β-phenylethylamine (PEA) by mitochondrial preparations of rabbit lung and brain was inhibited by imipramine. This tricyclic iminodibenzyl antidepressant drug was most effective in decreasing the deamination of PEA: at 1 × 10^?4M imipramine, deamination of PEA, Tyr and 5-HT was inhibited by approximately 70, 45 and 45 per cent, respectively, when either lung or brain mitochondrial monoamine oxidase (MAO) preparations were used. Imipramine-induced inhibition of MAO was shown to be of a mixed type based on Lineweaver-Burk plots, but was found to be completely reversible. The desmcthyl and didesmethyl derivatives of imipramine were equally as effective as the parent drug in inhibiting the deamination of PEA, whereas the N-oxide analog of imipramine was less effective as an inhibitor of this reaction. These results support the premise that the action of imipramine as a clinically effective antidepressive agent may be related to its inhibitory effect on the specific form of MAO which deaminates PEA.     

Augmentation by serrapeptase of tissue permeation by cefotiam

Cefotiam (CTM) is a new cephalosporin with a broad spectrum of activity against both Gram-positive and Gram-negative microorganisms. Cephalosporins are widely used for prophylaxis of infections in patients undergoing thoracotomy. Augmentation by serrapeptase on tissue permeation of CTM was examined in 35 thoracotomy patients with lung cancer. The subjects were divided into two groups according to the method of the administration of CTM. Group I consisted of 17 subjects, each of whom received a single dose of 2 g of CTM alone by an instillation for 30 minutes. Group II consisted of 18 subjects, each of whom received a combination of CTM and serrapeptase; serrapeptase was given 2 tablets (10 mg) each time for three times/day until the day before surgery, and then CTM was administered by the same procedure. The following results were obtained: Individual difference was observed for the permeation of CTM into tissues. Pathologic differences also affected the permeation. Nevertheless, the CTM levels in pulmonary tissues reached about a half of those in the blood in both the single dose group and the combination group, hence sufficient concentrations exceeding MIC80 for main microorganisms that caused infections in the lung were obtained. The concentrations of CTM in inflammatory tissues have showed lower levels than those of normal tissues in both CTM single dose and the combination groups. Decrease of blood flow volume may have contributed to the reduction in levels of CTM in the inflammatory tissues. The ratio of the concentration of the drug in pulmonary tissues to that in the blood was 29.1 +/- 2.5% in the single dose group, and 44.2 +/- 6.0% in the combination group, the latter showing quite a significant increase (P less than 0.05). Combined administrations of CTM and serrapeptase deserves more trials in the case when surgical treatments of the lung are performed. An antiinflammatory effect of serrapeptase in the respiratory system is expected, and in addition, the combined use of CTM and serrapeptase should stimulate permeation of the antibiotic into tissues.     

Immunomodulation by non-absorbable antibiotics given by the intragastric route

To test the role of bacterial fractions released from intestinal flora during immunomodulation by antimicrobial agents, BALB/c mice were treated with the non-absorbable antibiotics polymyxin B or teicoplanin by the intragastric route. The composition of faecal microbiota and the capacity of spleen cells to proliferate in response to B-cell and T-cell mitogens were assessed at several times during the treatment. Both antibiotics lowered the count of some bacteria of the intestinal flora and induced significant modifications in spleen cell ability to proliferate in response to mitogens. Thus, the active fractions released from intestinal bacteria during antibiotic treatments may be able to induce immunomodulating effects.